sorafenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors	2459	284461-73-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: BAY 43-9006 BAY 545-9085 BAY-545-9085 sorafenib tosilate sorafenib nexavar sorafenib tosylate	Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma. Molecular weight: 464.83 Formula: C21H16ClF3N4O3 CLOGP: 5.16 LIPINSKI: 1 HAC: 7 HDO: 3 TPSA: 92.35 ALOGS: -5.43 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

BAY 43-9006
BAY 545-9085
BAY-545-9085
sorafenib tosilate
sorafenib
nexavar
sorafenib tosylate

Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.

Molecular weight: 464.83
Formula: C21H16ClF3N4O3
CLOGP: 5.16
LIPINSKI: 1
HAC: 7
HDO: 3
TPSA: 92.35
ALOGS: -5.43
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	12.29 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	39 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
July 19, 2006	EMA	BAYER AG
Dec. 20, 2005	FDA	BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome	1639.20	20.15	471	14654	22544	63451353
Hepatic function abnormal	225.99	20.15	129	14996	37013	63436884
Hepatic cancer	211.46	20.15	67	15058	4420	63469477
Diarrhoea	210.05	20.15	498	14627	714868	62759029
Hepatic encephalopathy	180.86	20.15	76	15049	11206	63462691
Decreased appetite	167.15	20.15	249	14876	250803	63223094
Off label use	138.75	20.15	412	14713	674050	62799847
Metastases to lung	134.22	20.15	64	15061	12686	63461211
Rash	129.14	20.15	357	14768	560514	62913383
Hypertension	118.96	20.15	227	14898	279076	63194821
Hyperkeratosis	115.05	20.15	46	15079	5972	63467925
Ascites	111.54	20.15	86	15039	40642	63433255
Skin exfoliation	98.81	20.15	82	15043	43020	63430877
Blister	98.21	20.15	137	14988	129677	63344220
Hepatocellular carcinoma	92.05	20.15	30	15095	2164	63471733
Drug ineffective	89.90	20.15	71	15054	1044694	62429203
Amylase increased	86.08	20.15	38	15087	6307	63467590
Alpha 1 foetoprotein increased	83.49	20.15	17	15108	177	63473720
Dry skin	75.74	20.15	80	15045	56807	63417090
Lipase increased	70.02	20.15	38	15087	9862	63464035
Hepatic failure	69.83	20.15	62	15063	35594	63438303
Pain of skin	69.60	20.15	40	15085	11594	63462303
Alopecia	63.12	20.15	200	14925	337336	63136561
Stomatitis	61.67	20.15	115	15010	138610	63335287
Erythema multiforme	60.93	20.15	35	15090	10134	63463763
Pneumonia adenoviral	58.25	20.15	12	15113	133	63473764
Erythema	54.92	20.15	126	14999	175625	63298272
Product use in unapproved indication	54.44	20.15	127	14998	178953	63294944
Skin toxicity	53.71	20.15	25	15100	4689	63469208
Ammonia increased	50.91	20.15	24	15101	4632	63469265
Drug hypersensitivity	50.66	20.15	7	15118	310680	63163217
Blood bilirubin increased	49.01	20.15	52	15073	37088	63436809
Rheumatoid arthritis	48.57	20.15	3	15122	253816	63220081
Adenoviral hepatitis	46.10	20.15	12	15113	389	63473508
Arthropathy	44.25	20.15	3	15122	234789	63239108
Condition aggravated	43.13	20.15	21	15104	402196	63071701
Platelet count decreased	42.79	20.15	89	15036	116033	63357864
Death	40.95	20.15	187	14938	374194	63099703
Food refusal	37.27	20.15	10	15115	365	63473532
Catabolic state	35.92	20.15	7	15118	57	63473840
Blood pressure increased	35.84	20.15	102	15023	161960	63311937
Mucosal inflammation	34.64	20.15	49	15076	46879	63427018
Protein induced by vitamin K absence or antagonist II increased	34.36	20.15	5	15120	3	63473894
Weight decreased	33.83	20.15	143	14982	276655	63197242
Pain in extremity	33.60	20.15	162	14963	331324	63142573
Swelling	33.31	20.15	12	15113	275366	63198531
Hypophosphataemia	33.18	20.15	25	15100	11401	63462496
Sinusitis	32.77	20.15	7	15118	226646	63247251
Liver carcinoma ruptured	32.34	20.15	5	15120	7	63473890
Joint swelling	32.33	20.15	19	15106	327647	63146250
Hyperammonaemia	31.32	20.15	18	15107	5214	63468683
Treatment failure	31.23	20.15	5	15120	199038	63274859
Oral pain	30.98	20.15	36	15089	28358	63445539
Abdominal pain	30.88	20.15	145	14980	293311	63180586
Weight increased	30.48	20.15	12	15113	260780	63213117
Pancreatic enzymes increased	30.27	20.15	10	15115	752	63473145
Renal cell carcinoma	29.87	20.15	15	15110	3320	63470577
Acute myeloid leukaemia recurrent	29.61	20.15	12	15113	1611	63472286
Tumour necrosis	29.57	20.15	10	15115	809	63473088
Hospitalisation	28.77	20.15	63	15062	85018	63388879
Pyrexia	27.58	20.15	199	14926	470279	63003618
Plantar erythema	27.13	20.15	7	15118	219	63473678
Liver disorder	27.00	20.15	47	15078	53640	63420257
Nasopharyngitis	26.14	20.15	14	15111	254243	63219654
Pain	26.10	20.15	90	15035	740538	62733359
Jaundice	25.31	20.15	33	15092	29218	63444679
Hypersensitivity	24.83	20.15	20	15105	292665	63181232
Discomfort	24.53	20.15	5	15120	167369	63306528
Disease progression	24.01	20.15	74	15051	122684	63351213
Palmoplantar keratoderma	23.98	20.15	11	15114	1996	63471901
Malignant neoplasm progression	23.57	20.15	57	15068	82064	63391833
Metastases to bone	23.52	20.15	27	15098	20992	63452905
Asthenia	23.47	20.15	164	14961	383440	63090457
Dysphonia	23.06	20.15	41	15084	47573	63426324
Tumour haemorrhage	22.87	20.15	10	15115	1621	63472276
Tumour thrombosis	22.38	20.15	4	15121	19	63473878
Arthralgia	22.30	20.15	66	15059	569644	62904253
Metastatic renal cell carcinoma	21.95	20.15	8	15117	806	63473091
Haematotoxicity	21.80	20.15	18	15107	9358	63464539
Hypocalcaemia	21.77	20.15	32	15093	31681	63442216
Wound	21.72	20.15	6	15119	163257	63310640
Skin lesion	21.09	20.15	31	15094	30690	63443207
Febrile neutropenia	20.97	20.15	69	15056	118380	63355517
Bone marrow failure	20.75	20.15	30	15095	29260	63444637
Adenovirus infection	20.61	20.15	12	15113	3559	63470338
Soft tissue necrosis	20.53	20.15	7	15118	580	63473317
Asthma	20.47	20.15	3	15122	127558	63346339

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome	3852.14	16.32	1183	34811	15612	34905325
Hepatic cancer	832.01	16.32	315	35679	7960	34912977
Hepatic function abnormal	666.79	16.32	467	35527	43896	34877041
Hepatic encephalopathy	600.61	16.32	296	35698	14389	34906548
Diarrhoea	590.66	16.32	1258	34736	388654	34532283
Ascites	464.41	16.32	384	35610	46187	34874750
Decreased appetite	461.92	16.32	701	35293	165691	34755246
Hypertension	418.92	16.32	603	35391	135840	34785097
Metastases to lung	381.35	16.32	188	35806	9132	34911805
Hepatic failure	357.21	16.32	291	35703	34240	34886697
Alopecia	307.59	16.32	231	35763	24124	34896813
Alpha 1 foetoprotein increased	287.40	16.32	78	35916	629	34920308
Blister	273.62	16.32	210	35784	22648	34898289
Dysphonia	245.80	16.32	199	35795	23184	34897753
Rash	198.63	16.32	590	35404	222162	34698775
Amylase increased	168.65	16.32	94	35900	5874	34915063
Ammonia increased	146.25	16.32	77	35917	4292	34916645
Liver carcinoma ruptured	141.40	16.32	34	35960	157	34920780
Blood bilirubin increased	134.54	16.32	181	35813	38115	34882822
Jaundice	126.48	16.32	160	35834	31722	34889215
Hepatocellular carcinoma	119.44	16.32	82	35912	7427	34913510
Drug ineffective	113.84	16.32	185	35809	456566	34464371
Hyperkeratosis	111.28	16.32	61	35933	3688	34917249
Stomatitis	110.13	16.32	174	35820	42340	34878597
Oesophageal varices haemorrhage	109.74	16.32	57	35937	3089	34917848
Skin exfoliation	106.16	16.32	136	35858	27296	34893641
Toxicity to various agents	106.12	16.32	37	35957	200325	34720612
Lipase increased	104.99	16.32	83	35911	9333	34911604
Liver disorder	103.95	16.32	148	35846	32849	34888088
Fatigue	97.43	16.32	683	35311	369970	34550967
Metastases to bone	95.42	16.32	87	35907	11883	34909054
Skin toxicity	89.99	16.32	58	35936	4726	34916211
Metastases to lymph nodes	88.14	16.32	57	35937	4671	34916266
Acute kidney injury	87.13	16.32	112	35882	304876	34616061
Drug interaction	86.45	16.32	64	35930	225882	34695055
Tumour rupture	84.09	16.32	24	35970	237	34920700
Portal vein thrombosis	81.48	16.32	50	35944	3738	34917199
Completed suicide	81.18	16.32	5	35989	98163	34822774
Dry skin	75.47	16.32	124	35870	31163	34889774
Renal cell carcinoma	75.30	16.32	53	35941	4995	34915942
Overdose	74.21	16.32	5	35989	91054	34829883
Hypophosphataemia	70.56	16.32	71	35923	10955	34909982
Abdominal pain upper	65.88	16.32	192	35802	71298	34849639
Platelet count decreased	65.26	16.32	270	35724	119447	34801490
Metastases to adrenals	65.20	16.32	28	35966	984	34919953
Abdominal pain	64.13	16.32	335	35659	163283	34757654
COVID-19	63.96	16.32	4	35990	77546	34843391
Acute myeloid leukaemia recurrent	63.55	16.32	35	35959	2135	34918802
Erythema multiforme	63.40	16.32	60	35934	8589	34912348
Asthenia	61.89	16.32	448	35546	244803	34676134
Aspartate aminotransferase increased	61.45	16.32	181	35813	67602	34853335
Weight decreased	60.39	16.32	348	35646	175953	34744984
Blood pressure increased	59.73	16.32	213	35781	87889	34833048
Hepatorenal syndrome	59.41	16.32	36	35958	2630	34918307
Tumour thrombosis	53.56	16.32	14	35980	96	34920841
Pain in extremity	53.00	16.32	264	35730	126249	34794688
Pain of skin	51.84	16.32	46	35948	6063	34914874
Condition aggravated	51.32	16.32	74	35920	192122	34728815
Protein induced by vitamin K absence or antagonist II increased	50.48	16.32	10	35984	13	34920924
Drug hypersensitivity	49.77	16.32	11	35983	80518	34840419
Fall	49.51	16.32	83	35911	202802	34718135
Metastatic renal cell carcinoma	48.96	16.32	29	35965	2032	34918905
Pancreatic enzymes increased	48.56	16.32	20	35974	632	34920305
Metastases to spine	47.79	16.32	31	35963	2553	34918384
Coma hepatic	47.39	16.32	18	35976	457	34920480
Gait inability	47.01	16.32	80	35914	20678	34900259
Hypotension	46.77	16.32	99	35895	221550	34699387
Neutropenia	46.30	16.32	56	35938	156722	34764215
Metastases to central nervous system	45.61	16.32	49	35945	8156	34912781
Skin fissures	45.42	16.32	40	35954	5219	34915718
Pneumonia	44.67	16.32	207	35787	362420	34558517
Metastases to peritoneum	43.95	16.32	26	35968	1818	34919119
Cerebral infarction	40.25	16.32	88	35906	27367	34893570
Weight increased	38.65	16.32	24	35970	93009	34827928
Liver abscess	38.48	16.32	32	35962	3863	34917074
Tumour marker increased	38.44	16.32	17	35977	642	34920295
Hepatic lesion	37.72	16.32	31	35963	3681	34917256
Hepatic rupture	37.18	16.32	9	35985	43	34920894
Malignant neoplasm progression	36.32	16.32	183	35811	87863	34833074
Nephrotic syndrome	36.07	16.32	41	35953	7262	34913675
Off label use	35.42	16.32	617	35377	418907	34502030
Gastric ulcer	35.02	16.32	60	35934	15590	34905347
Inappropriate schedule of product administration	33.79	16.32	11	35983	62285	34858652
Cardiac arrest	33.26	16.32	30	35964	96129	34824808
Tumour haemorrhage	32.78	16.32	26	35968	2936	34918001
Product administered to patient of inappropriate age	32.43	16.32	27	35967	3264	34917673
Reactive perforating collagenosis	31.13	16.32	6	35988	6	34920931
Intentional product misuse	30.79	16.32	5	35989	45606	34875331
Pyrexia	30.70	16.32	497	35497	332516	34588421
Intentional product use issue	30.00	16.32	12	35982	59804	34861133
Keratoacanthoma	29.24	16.32	14	35980	636	34920301
Bradycardia	29.24	16.32	21	35973	75397	34845540
Therapeutic product effect incomplete	29.09	16.32	8	35986	50533	34870404
Coronary artery disease	29.04	16.32	7	35987	48298	34872639
Metastasis	28.95	16.32	28	35966	4116	34916821
Anxiety	28.81	16.32	36	35958	99392	34821545
Cancer pain	28.60	16.32	23	35971	2649	34918288
Hyperammonaemia	28.53	16.32	34	35960	6333	34914604
Hospitalisation	28.37	16.32	125	35869	56777	34864160
Epistaxis	28.32	16.32	127	35867	58124	34862813
Bone marrow failure	28.30	16.32	80	35914	29173	34891764
Erythema	28.23	16.32	172	35822	88608	34832329
Death	28.22	16.32	570	35424	397479	34523458
Haematemesis	28.01	16.32	77	35917	27634	34893303
Prostate cancer	27.55	16.32	4	35990	39645	34881292
Febrile neutropenia	27.28	16.32	63	35931	136786	34784151
Alanine aminotransferase increased	27.25	16.32	159	35835	80656	34840281
Malaise	26.88	16.32	301	35693	185524	34735413
Hyperamylasaemia	26.62	16.32	13	35981	617	34920320
Agitation	26.45	16.32	13	35981	57386	34863551
Depression	26.25	16.32	37	35957	97061	34823876
Incorrect dose administered	26.13	16.32	5	35989	40510	34880427
Suicidal ideation	26.01	16.32	5	35989	40383	34880554
Septal panniculitis	25.73	16.32	7	35987	57	34920880
Haemobilia	25.44	16.32	11	35983	393	34920544
Lactic acidosis	25.38	16.32	3	35991	34769	34886168
Therapeutic product effect decreased	25.35	16.32	3	35991	34740	34886197
Metastases to liver	24.99	16.32	48	35946	13615	34907322
Sinusitis	24.88	16.32	6	35988	41396	34879541
Genital rash	24.64	16.32	12	35982	566	34920371
Varicose vein ruptured	24.44	16.32	7	35987	70	34920867
Glossodynia	24.03	16.32	24	35970	3669	34917268
Plantar erythema	24.01	16.32	7	35987	75	34920862
Product dose omission issue	23.94	16.32	55	35939	119656	34801281
Varices oesophageal	23.69	16.32	24	35970	3731	34917206
Proteinuria	23.17	16.32	56	35938	18586	34902351
Wheezing	23.00	16.32	7	35987	41395	34879542
Gastric antral vascular ectasia	22.96	16.32	10	35984	364	34920573
Gingival bleeding	22.92	16.32	32	35962	6968	34913969
Chronic obstructive pulmonary disease	22.65	16.32	11	35983	48907	34872030
Asthma	22.32	16.32	8	35986	42648	34878289
Tachycardia	22.23	16.32	33	35961	84739	34836198
General physical health deterioration	21.93	16.32	215	35779	128054	34792883
Hepatic cancer metastatic	21.78	16.32	12	35982	732	34920205
Hyperhidrosis	21.31	16.32	28	35966	75664	34845273
Neuropathy peripheral	21.27	16.32	33	35961	83230	34837707
Hypersensitivity	21.14	16.32	19	35975	61016	34859921
Faeces discoloured	21.02	16.32	47	35947	14831	34906106
Melaena	20.99	16.32	82	35912	35298	34885639
Oxygen saturation decreased	20.84	16.32	15	35979	53803	34867134
Hepatic infarction	20.78	16.32	8	35986	211	34920726
Skin ulcer	20.75	16.32	60	35934	22156	34898781
Nasopharyngitis	20.62	16.32	25	35969	69943	34850994
Rhabdomyolysis	20.46	16.32	24	35970	68139	34852798
Hepatic cirrhosis	20.45	16.32	51	35943	17263	34903674
Influenza	20.36	16.32	13	35981	49653	34871284
Joint swelling	20.32	16.32	19	35975	59871	34861066
Abdominal distension	20.30	16.32	116	35878	58376	34862561
Lower respiratory tract infection	20.20	16.32	4	35990	31633	34889304
Hepatic artery thrombosis	19.81	16.32	8	35986	240	34920697
Metastases to heart	19.63	16.32	7	35987	148	34920789
Chronic kidney disease	19.49	16.32	9	35985	41201	34879736
Stress	19.04	16.32	4	35990	30343	34890594
Glossitis	18.59	16.32	13	35981	1212	34919725
Wrong technique in product usage process	18.40	16.32	7	35987	35979	34884958
Aortic dissection	18.03	16.32	18	35976	2750	34918187
Tumour necrosis	18.00	16.32	13	35981	1275	34919662
Oropharyngeal blistering	17.92	16.32	7	35987	192	34920745
Gastrointestinal perforation	17.92	16.32	21	35973	3842	34917095
Encephalopathy	17.91	16.32	78	35916	35241	34885696
Hypoalbuminaemia	17.81	16.32	39	35955	12135	34908802
Blood lactate dehydrogenase increased	17.67	16.32	58	35936	22932	34898005
Graft versus host disease in skin	17.65	16.32	21	35973	3904	34917033
Thyroid atrophy	17.64	16.32	3	35991	0	34920937
Metastases to gallbladder	17.64	16.32	3	35991	0	34920937
Drug reaction with eosinophilia and systemic symptoms	17.60	16.32	6	35988	33006	34887931
Thyroid cancer metastatic	17.28	16.32	5	35989	52	34920885
Feeding disorder	17.18	16.32	28	35966	6982	34913955
Food refusal	17.03	16.32	7	35987	220	34920717
Tumour embolism	16.79	16.32	5	35989	58	34920879
Syncope	16.72	16.32	44	35950	91407	34829530
Urticaria	16.63	16.32	24	35970	62353	34858584
Albumin urine present	16.46	16.32	8	35986	376	34920561
Electrocardiogram QT prolonged	16.40	16.32	11	35983	40941	34879996

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome	5197.11	16.84	1531	45283	31603	79665971
Hepatic cancer	997.89	16.84	332	46482	10197	79687377
Hepatic function abnormal	898.53	16.84	550	46264	72557	79625017
Hepatic encephalopathy	774.54	16.84	346	46468	23820	79673754
Diarrhoea	721.46	16.84	1586	45228	878903	78818671
Decreased appetite	619.38	16.84	876	45938	341542	79356032
Ascites	574.53	16.84	422	46392	75140	79622434
Metastases to lung	506.12	16.84	236	46578	17927	79679647
Hypertension	477.05	16.84	762	46052	330230	79367344
Hepatic failure	420.91	16.84	322	46492	60890	79636684
Alpha 1 foetoprotein increased	366.98	16.84	87	46727	721	79696853
Rash	254.95	16.84	831	45983	577527	79120047
Amylase increased	243.88	16.84	123	46691	11086	79686488
Hepatocellular carcinoma	226.07	16.84	109	46705	8912	79688662
Dysphonia	221.04	16.84	216	46598	56656	79640918
Hyperkeratosis	207.01	16.84	98	46716	7692	79689882
Blister	202.34	16.84	297	46517	119179	79578395
Skin exfoliation	198.84	16.84	201	46613	54899	79642675
Lipase increased	184.53	16.84	117	46697	16349	79681225
Blood bilirubin increased	180.01	16.84	208	46606	66024	79631550
Drug ineffective	176.00	16.84	227	46587	1080686	78616888
Ammonia increased	175.58	16.84	87	46727	7548	79690026
Jaundice	168.08	16.84	181	46633	53168	79644406
Liver carcinoma ruptured	164.72	16.84	35	46779	164	79697410
Alopecia	155.78	16.84	388	46426	230967	79466607
Dry skin	143.49	16.84	188	46626	67807	79629767
Skin toxicity	140.34	16.84	77	46737	8237	79689337
Platelet count decreased	135.80	16.84	331	46483	194333	79503241
Oesophageal varices haemorrhage	133.52	16.84	60	46754	4176	79693398
Drug hypersensitivity	126.36	16.84	14	46800	298902	79398672
Off label use	123.29	16.84	931	45883	906284	78791290
Completed suicide	122.67	16.84	5	46809	245762	79451812
Stomatitis	117.00	16.84	263	46551	146494	79551080
Renal cell carcinoma	114.01	16.84	62	46752	6516	79691058
Liver disorder	113.91	16.84	174	46640	72243	79625331
Death	109.91	16.84	636	46178	565878	79131696
Rheumatoid arthritis	104.85	16.84	4	46810	208466	79489108
Erythema multiforme	104.30	16.84	85	46729	17566	79680008
Hypophosphataemia	101.39	16.84	88	46726	19825	79677749
Portal vein thrombosis	101.21	16.84	55	46759	5772	79691802
Metastases to bone	100.94	16.84	96	46718	24331	79673243
Pain of skin	100.61	16.84	77	46737	14536	79683038
Toxicity to various agents	100.02	16.84	62	46752	421478	79276096
Condition aggravated	98.04	16.84	90	46724	501034	79196540
Weight decreased	97.66	16.84	440	46374	354758	79342816
Acute myeloid leukaemia recurrent	97.43	16.84	45	46769	3338	79694236
Asthenia	95.65	16.84	569	46245	511120	79186454
Tumour rupture	91.99	16.84	26	46788	453	79697121
Weight increased	91.20	16.84	25	46789	277361	79420213
Overdose	87.88	16.84	5	46809	184201	79513373
Metastases to lymph nodes	85.56	16.84	61	46753	10336	79687238
Fatigue	84.47	16.84	874	45940	928853	78768721
Blood pressure increased	83.15	16.84	293	46521	211067	79486507
Joint swelling	82.66	16.84	33	46781	288613	79408961
Protein induced by vitamin K absence or antagonist II increased	79.99	16.84	14	46800	15	79697559
Therapeutic product effect decreased	79.57	16.84	4	46810	163859	79533715
Sinusitis	78.09	16.84	11	46803	195490	79502084
Malignant neoplasm progression	78.03	16.84	215	46599	135775	79561799
Metastases to adrenals	76.62	16.84	29	46785	1301	79696273
Abdominal pain	74.49	16.84	436	46378	389133	79308441
Aspartate aminotransferase increased	74.46	16.84	214	46600	138427	79559147
Pancreatic enzymes increased	72.31	16.84	28	46786	1337	79696237
Nasopharyngitis	71.10	16.84	30	46784	253851	79443723
Tumour thrombosis	70.65	16.84	17	46797	151	79697423
Fall	70.43	16.84	111	46703	487518	79210056
Hypersensitivity	70.28	16.84	33	46781	262206	79435368
COVID-19	70.23	16.84	6	46808	157668	79539906
Hospitalisation	68.58	16.84	163	46651	94073	79603501
Pyrexia	64.79	16.84	645	46169	678064	79019510
Bone marrow failure	64.29	16.84	111	46703	50996	79646578
Drug interaction	63.33	16.84	91	46723	415092	79282482
Metastases to spine	62.02	16.84	36	46778	4288	79693286
Lower respiratory tract infection	60.14	16.84	4	46810	129216	79568358
Hepatorenal syndrome	59.95	16.84	35	46779	4214	79693360
Arthralgia	59.72	16.84	157	46657	571646	79125928
Cerebral infarction	58.50	16.84	100	46714	45576	79651998
Hypotension	58.25	16.84	106	46708	440211	79257363
Liver abscess	57.99	16.84	39	46775	6015	79691559
Metastases to central nervous system	57.69	16.84	59	46755	16316	79681258
Coma hepatic	56.02	16.84	22	46792	1091	79696483
Pain in extremity	56.00	16.84	386	46428	364152	79333422
Hyperammonaemia	54.41	16.84	48	46766	11045	79686529
Tumour haemorrhage	52.90	16.84	32	46782	4112	79693462
Inappropriate schedule of product administration	52.24	16.84	8	46806	133620	79563954
Gait inability	50.76	16.84	109	46705	58808	79638766
Skin fissures	49.54	16.84	49	46765	13024	79684550
Product administered to patient of inappropriate age	48.99	16.84	34	46780	5519	79692055
Asthma	48.65	16.84	10	46804	135085	79562489
Hepatic lesion	48.63	16.84	37	46777	6922	79690652
Therapeutic product effect incomplete	47.98	16.84	12	46802	141633	79555941
Erythema	47.28	16.84	257	46557	223033	79474541
Food refusal	46.49	16.84	16	46798	544	79697030
Treatment failure	44.82	16.84	22	46792	170464	79527110
Tumour necrosis	44.48	16.84	22	46792	1900	79695674
Nephrotic syndrome	44.43	16.84	43	46771	11131	79686443
Intentional product use issue	44.15	16.84	17	46797	152095	79545479
Metastases to peritoneum	43.89	16.84	29	46785	4343	79693231
Anxiety	43.53	16.84	49	46765	248463	79449111
Swelling	43.39	16.84	38	46776	216673	79480901
Metastatic renal cell carcinoma	43.05	16.84	23	46791	2332	79695242
Musculoskeletal stiffness	42.47	16.84	25	46789	174983	79522591
Plantar erythema	42.27	16.84	13	46801	307	79697267
Varices oesophageal	42.19	16.84	32	46782	5959	79691615
Cancer pain	41.38	16.84	30	46784	5215	79692359
Product use in unapproved indication	41.34	16.84	270	46544	250089	79447485
Pericarditis	41.29	16.84	6	46808	104230	79593344
Acute kidney injury	40.68	16.84	162	46652	519242	79178332
Pleural effusion	40.60	16.84	181	46633	145081	79552493
Hepatic rupture	40.49	16.84	10	46804	100	79697474
Metastasis	40.37	16.84	33	46781	6847	79690727
Metastases to liver	40.29	16.84	65	46749	28249	79669325
Proteinuria	40.10	16.84	70	46744	32432	79665142
Epistaxis	39.91	16.84	150	46664	111365	79586209
Pain	39.39	16.84	247	46567	703555	78994019
Wheezing	37.41	16.84	11	46803	116653	79580921
Gastric ulcer	36.71	16.84	69	46745	33836	79663738
Blood lactate dehydrogenase increased	36.69	16.84	75	46739	39095	79658479
Arthritis	36.53	16.84	11	46803	114869	79582705
Discomfort	36.52	16.84	14	46800	125603	79571971
Alanine aminotransferase increased	35.67	16.84	189	46625	162381	79535193
Bronchitis	35.66	16.84	16	46798	130628	79566946
Wound	35.39	16.84	12	46802	116167	79581407
Reactive perforating collagenosis	34.49	16.84	6	46808	6	79697568
Gingival bleeding	34.30	16.84	45	46769	16231	79681343
Abdominal pain upper	33.72	16.84	236	46578	223583	79473991
Headache	32.78	16.84	237	46577	653535	79044039
Abdominal distension	32.61	16.84	148	46666	119502	79578072
Pneumonia adenoviral	32.55	16.84	12	46802	500	79697074
Intentional product misuse	32.34	16.84	8	46806	95157	79602417
Haematemesis	32.33	16.84	85	46729	52179	79645395
Upper respiratory tract infection	32.30	16.84	7	46807	91161	79606413
Oxygen saturation decreased	31.92	16.84	18	46796	129029	79568545
Dehydration	31.89	16.84	252	46562	247935	79449639
Injury	31.79	16.84	4	46810	77492	79620082
Melaena	31.71	16.84	93	46721	60797	79636777
Gastric antral vascular ectasia	31.57	16.84	14	46800	944	79696630
Catabolic state	31.38	16.84	8	46806	92	79697482
Oropharyngeal blistering	30.89	16.84	13	46801	771	79696803
Cardiac arrest	30.05	16.84	34	46780	172062	79525512
Oral pain	29.92	16.84	61	46753	31737	79665837
Dysphagia	29.58	16.84	146	46668	121990	79575584
Palmoplantar keratoderma	28.74	16.84	21	46793	3695	79693879
Pneumonia	28.62	16.84	249	46565	659997	79037577
Migraine	28.51	16.84	8	46806	87485	79610089
Stress	28.44	16.84	6	46808	79606	79617968
Osteoarthritis	28.42	16.84	8	46806	87301	79610273
Influenza	28.08	16.84	21	46793	129585	79567989
Bradycardia	28.06	16.84	23	46791	135534	79562040
Depression	27.90	16.84	53	46761	216737	79480837
Lymphadenopathy mediastinal	27.73	16.84	22	46792	4374	79693200
Keratoacanthoma	27.31	16.84	13	46801	1032	79696542
Medication error	27.07	16.84	4	46810	68638	79628936
Gastrointestinal perforation	27.04	16.84	25	46789	6112	79691462
Nasal congestion	26.88	16.84	6	46808	76546	79621028
Hypocalcaemia	26.71	16.84	77	46737	49847	79647727
Hypoalbuminaemia	26.44	16.84	46	46768	21251	79676323
Glossitis	26.43	16.84	20	46794	3710	79693864
General physical health deterioration	26.33	16.84	262	46552	274976	79422598
Hyperamylasaemia	26.16	16.84	13	46801	1134	79696440
Duodenal ulcer perforation	25.79	16.84	4	46810	66207	79631367
Adenoviral hepatitis	25.67	16.84	12	46802	915	79696659
Skin ulcer	25.65	16.84	80	46734	54070	79643504
Hyperbilirubinaemia	25.43	16.84	49	46765	24469	79673105
Faeces discoloured	25.21	16.84	54	46760	29073	79668501
Urinary tract infection	25.20	16.84	80	46734	274432	79423142
Haemobilia	25.05	16.84	10	46804	518	79697056
Incorrect dose administered	24.98	16.84	7	46807	76623	79620951
Urticaria	24.96	16.84	44	46770	185157	79512417
Anaphylactic reaction	24.90	16.84	9	46805	83734	79613840
Cholangitis	24.90	16.84	34	46780	12742	79684832
Suicidal ideation	24.83	16.84	7	46807	76333	79621241
Fluid intake reduced	24.63	16.84	24	46790	6264	79691310
Blood albumin decreased	24.60	16.84	48	46766	24195	79673379
Aortic dissection	24.44	16.84	20	46794	4155	79693419
Septal panniculitis	24.30	16.84	7	46807	131	79697443
Neutropenia	24.26	16.84	87	46727	287623	79409951
Mucosal inflammation	24.06	16.84	98	46716	75482	79622092
Tumour marker increased	24.04	16.84	20	46794	4252	79693322
Renal cell carcinoma stage IV	23.61	16.84	6	46808	68	79697506
Hepatic cancer metastatic	23.30	16.84	11	46803	857	79696717
Blood cholesterol increased	23.24	16.84	10	46804	83710	79613864
Haemoptysis	23.16	16.84	79	46735	55920	79641654
Gastrointestinal toxicity	22.91	16.84	26	46788	8083	79689491
Metastases to abdominal cavity	22.84	16.84	10	46804	654	79696920
Metastases to heart	22.84	16.84	8	46806	287	79697287
Hyperhidrosis	22.27	16.84	34	46780	151458	79546116
Thyroid cancer metastatic	22.12	16.84	7	46807	182	79697392
Agitation	21.80	16.84	16	46798	99699	79597875
Hiccups	21.55	16.84	28	46786	10003	79687571
Cataract	21.54	16.84	5	46809	62115	79635459
Product dose omission issue	21.43	16.84	74	46740	247463	79450111
Feeding disorder	21.35	16.84	36	46778	16218	79681356
Rhinorrhoea	21.26	16.84	9	46805	76065	79621509
Gastrointestinal haemorrhage	21.21	16.84	154	46660	147565	79550009
Chronic obstructive pulmonary disease	21.00	16.84	12	46802	85407	79612167
Hepatic pain	20.73	16.84	18	46796	4054	79693520
Dizziness	20.43	16.84	204	46610	526237	79171337
Disease progression	20.36	16.84	181	46633	184181	79513393
Tumour pain	20.10	16.84	14	46800	2285	79695289
Eating disorder	19.82	16.84	40	46774	20657	79676917
Varicose vein ruptured	19.78	16.84	6	46808	135	79697439
Sleep disorder	19.72	16.84	13	46801	85664	79611910
Somnolence	19.65	16.84	73	46741	238908	79458666
Encephalopathy	19.59	16.84	85	46729	67312	79630262
Osteoporosis	19.49	16.84	4	46810	54108	79643466
Blood sodium decreased	19.47	16.84	53	46761	33202	79664372
Alpha 1 foetoprotein abnormal	19.19	16.84	5	46809	63	79697511
Skin lesion	19.06	16.84	61	46753	41783	79655791
Type 2 diabetes mellitus	19.03	16.84	5	46809	57117	79640457
Wrong technique in product usage process	18.71	16.84	10	46804	73865	79623709
Genital rash	18.68	16.84	10	46804	1018	79696556
Cognitive disorder	18.40	16.84	9	46805	69917	79627657
Tumour lysis syndrome	18.04	16.84	42	46772	23897	79673677
Coronary artery disease	17.89	16.84	8	46806	65466	79632108
Aggression	17.87	16.84	4	46810	50954	79646620
Illness	17.69	16.84	3	46811	46508	79651066
Gamma-glutamyltransferase increased	17.48	16.84	71	46743	54609	79642965
Gastrointestinal disorder	17.42	16.84	28	46786	122177	79575397
Metastases to pleura	17.30	16.84	11	46803	1543	79696031
Tongue blistering	17.27	16.84	11	46803	1548	79696026
Bleeding varicose vein	17.10	16.84	8	46806	611	79696963
Therapeutic response decreased	17.00	16.84	9	46805	66844	79630730

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EX02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors
CHEBI has role	CHEBI:48422	angiogenesis antagonist
CHEBI has role	CHEBI:50925	serine/threonine protein kinase inhibitor
CHEBI has role	CHEBI:149553	anticoronaviral drug
CHEBI has role	CHEBI:173085	ferroptosis inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Liver cell carcinoma	indication	109841003	DOID:684
Carcinoma of thyroid	indication	448216007
Renal cell carcinoma	indication	702391001	DOID:4450
Hypophosphatemia	contraindication	4996001
Acute hemorrhage	contraindication	8573003
Myocardial infarction	contraindication	22298006	DOID:5844
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal perforation	contraindication	51875005
Hepatic failure	contraindication	59927004
Blood coagulation disorder	contraindication	64779008	DOID:1247
Pancreatitis	contraindication	75694006	DOID:4989
Angina pectoris	contraindication	194828000
Impaired wound healing	contraindication	271618001
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Surgical procedure	contraindication	387713003
Acute coronary syndrome	contraindication	394659003
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.84	acidic
pKa2	11.97	acidic
pKa3	12.61	acidic
pKa4	2.76	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 200MG BASE	NEXAVAR	BAYER HLTHCARE	N021923	Dec. 20, 2005	RX	TABLET	ORAL	8618141	Feb. 11, 2023	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE	NEXAVAR	BAYER HLTHCARE	N021923	Dec. 20, 2005	RX	TABLET	ORAL	8877933	Dec. 24, 2027	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
EQ 200MG BASE	NEXAVAR	BAYER HLTHCARE	N021923	Dec. 20, 2005	RX	TABLET	ORAL	9737488	Sept. 10, 2028	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE	NEXAVAR	BAYER HLTHCARE	N021923	Dec. 20, 2005	RX	TABLET	ORAL	9737488	Sept. 10, 2028	TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
EQ 200MG BASE	NEXAVAR	BAYER HLTHCARE	N021923	Dec. 20, 2005	RX	TABLET	ORAL	9737488	Sept. 10, 2028	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN	INHIBITOR	Kd	7.80	CHEMBL	CHEMBL
RAF proto-oncogene serine/threonine-protein kinase	Kinase	P04049	RAF1_HUMAN	INHIBITOR	Ki	8.22	CHEMBL	CHEMBL
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN	INHIBITOR	Ki	7.66	CHEMBL	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN	INHIBITOR	Kd	8.35	CHEMBL	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN	INHIBITOR	Kd	8.13	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN	INHIBITOR	Kd	7.51	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	INHIBITOR	Ki	10.68	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 3	Kinase	P35916	VGFR3_HUMAN	INHIBITOR	Kd	7.80	CHEMBL	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN	INHIBITOR	Kd	7.43	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	5.48	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	6.89	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	8.53	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	5.09	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN		IC50	6.41	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	5.57	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		Kd	5.08	CHEMBL
Ephrin type-A receptor 2	Kinase	P29317	EPHA2_HUMAN		Kd	5.70	CHEMBL
Macrophage colony-stimulating factor 1 receptor	Kinase	P07333	CSF1R_HUMAN		Kd	7.55	CHEMBL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN		Kd	7.21	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	6.88	CHEMBL
Cyclin-dependent kinase 2	Kinase	P24941	CDK2_HUMAN		Kd	5.06	CHEMBL
Insulin receptor	Kinase	P06213	INSR_HUMAN	AGONIST	IC50	5.28	CHEMBL
Fibroblast growth factor receptor 3	Kinase	P22607	FGFR3_HUMAN		Kd	5.38	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	5.07	CHEMBL
High affinity nerve growth factor receptor	Kinase	P04629	NTRK1_HUMAN		Kd	5.44	CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle	Kinase	Q9H1R3	MYLK2_HUMAN		Kd	5.89	CHEMBL
Tyrosine-protein kinase CSK	Kinase	P41240	CSK_HUMAN		Kd	5.54	CHEMBL
Angiopoietin-1 receptor	Kinase	Q02763	TIE2_HUMAN		Kd	5.68	CHEMBL
Ephrin type-A receptor 8	Kinase	P29322	EPHA8_HUMAN		Kd	6.02	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		IC50	5.24	CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN		Kd	5.52	CHEMBL
LIM domain kinase 1	Kinase	P53667	LIMK1_HUMAN		Kd	5.80	CHEMBL
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN		Kd	5.60	CHEMBL
Cyclin-dependent-like kinase 5	Kinase	Q00535	CDK5_HUMAN		Kd	5.21	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	6.85	CHEMBL
Serine/threonine-protein kinase PLK4	Kinase	O00444	PLK4_HUMAN		Kd	5.47	CHEMBL
Aurora kinase C	Kinase	Q9UQB9	AURKC_HUMAN		Kd	6.68	CHEMBL
Dual specificity protein kinase TTK	Kinase	P33981	TTK_HUMAN		Kd	5.46	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	5.89	CHEMBL
Mitogen-activated protein kinase 11	Kinase	Q15759	MK11_HUMAN		Kd	6.70	CHEMBL
Ephrin type-A receptor 5	Kinase	P54756	EPHA5_HUMAN		Kd	6.44	CHEMBL
Ephrin type-A receptor 4	Kinase	P54764	EPHA4_HUMAN		Kd	5.89	CHEMBL
Fibroblast growth factor receptor 2	Kinase	P21802	FGFR2_HUMAN		Kd	5.57	CHEMBL
Mitogen-activated protein kinase 3	Kinase	P27361	MK03_HUMAN		IC50	7.74	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	6.62	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	5.10	CHEMBL
Mitogen-activated protein kinase 12	Kinase	P53778	MK12_HUMAN		Kd	5.12	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	5.11	CHEMBL
Aurora kinase A	Kinase	O14965	AURKA_HUMAN		IC50	5.42	CHEMBL
Serine/threonine-protein kinase 36	Kinase	Q9NRP7	STK36_HUMAN		Kd	5.42	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	5.72	CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		Kd	6.59	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	6.36	CHEMBL
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	5.12	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	5.80	CHEMBL
Glycogen synthase kinase-3 beta	Kinase	P49841	GSK3B_HUMAN		IC50	5.08	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	5.89	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN		Kd	5.77	CHEMBL
Ephrin type-A receptor 7	Kinase	Q15375	EPHA7_HUMAN		Kd	6.17	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	6	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	6.89	CHEMBL
Mitogen-activated protein kinase 9	Kinase	P45984	MK09_HUMAN		Kd	5.44	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	8.82	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN		Kd	5.74	CHEMBL
Cyclin-dependent kinase 15	Kinase	Q96Q40	CDK15_HUMAN		Kd	5.54	CHEMBL
Bifunctional epoxide hydrolase 2	Enzyme	P34913	HYES_HUMAN		IC50	7.92	CHEMBL
TGF-beta receptor type-2	Kinase	P37173	TGFR2_HUMAN		Kd	5.16	CHEMBL
Mitogen-activated protein kinase 1	Kinase	P28482	MK01_HUMAN		IC50	6.96	CHEMBL
Cyclin-dependent kinase 6	Kinase	Q00534	CDK6_HUMAN		IC50	6.89	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	5.35	CHEMBL
BDNF/NT-3 growth factors receptor	Kinase	Q16620	NTRK2_HUMAN		Kd	5.68	CHEMBL
Ephrin type-B receptor 2	Kinase	P29323	EPHB2_HUMAN		Kd	5.72	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	6.85	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	5.12	CHEMBL
Non-receptor tyrosine-protein kinase TNK1	Kinase	Q13470	TNK1_HUMAN		Kd	5.64	CHEMBL
Mitogen-activated protein kinase 13	Kinase	O15264	MK13_HUMAN		Kd	5.18	CHEMBL
Cyclin-dependent kinase 17	Kinase	Q00537	CDK17_HUMAN		Kd	5.80	CHEMBL
Cyclin-dependent kinase 14	Kinase	O94921	CDK14_HUMAN		Kd	5.54	CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		Kd	8.20	CHEMBL
Tyrosine-protein kinase receptor Tie-1	Kinase	P35590	TIE1_HUMAN		Kd	7.17	CHEMBL
NT-3 growth factor receptor	Kinase	Q16288	NTRK3_HUMAN		Kd	6.22	CHEMBL
LIM domain kinase 2	Kinase	P53671	LIMK2_HUMAN		Kd	5.02	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1	Kinase	Q9BUB5	MKNK1_HUMAN		Kd	6.64	CHEMBL
Serine/threonine-protein kinase NLK	Kinase	Q9UBE8	NLK_HUMAN		Kd	6.19	CHEMBL
Serine/threonine-protein kinase 33	Kinase	Q9BYT3	STK33_HUMAN		Kd	5.62	CHEMBL
Serine/threonine-protein kinase TNNI3K	Kinase	Q59H18	TNI3K_HUMAN		Kd	6.55	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	8.18	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1	Kinase	Q92918	M4K1_HUMAN		Kd	5.32	CHEMBL
Aurora kinase B	Kinase	Q96GD4	AURKB_HUMAN		Kd	6.36	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4	Kinase	O95819	M4K4_HUMAN		Kd	5.32	CHEMBL
Tyrosine-protein kinase Mer	Kinase	Q12866	MERTK_HUMAN		Kd	5.44	CHEMBL
Cyclin-dependent kinase 19	Kinase	Q9BWU1	CDK19_HUMAN		Kd	6.60	CHEMBL
Cyclin-dependent kinase 8	Kinase	P49336	CDK8_HUMAN		Kd	6.51	CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase	Kinase	O15146	MUSK_HUMAN		Kd	6.89	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.21	CHEMBL
Myosin-IIIb	Kinase	Q8WXR4	MYO3B_HUMAN		Kd	5.15	CHEMBL
Cyclin-dependent kinase 3	Kinase	Q00526	CDK3_HUMAN		Kd	5.42	CHEMBL
Tyrosine-protein kinase Srms	Kinase	Q9H3Y6	SRMS_HUMAN		Kd	5.01	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN		Kd	5.51	CHEMBL
Receptor-interacting serine/threonine-protein kinase 1	Kinase	Q13546	RIPK1_HUMAN		IC50	5.82	CHEMBL
Casein kinase I isoform alpha	Kinase	P48729	KC1A_HUMAN		IC50	6.60	CHEMBL
Cyclin-dependent kinase-like 2	Kinase	Q92772	CDKL2_HUMAN		Kd	6.89	CHEMBL
Cyclin-dependent kinase-like 3	Kinase	Q8IVW4	CDKL3_HUMAN		Kd	6.31	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	6.62	CHEMBL
Homeodomain-interacting protein kinase 2	Kinase	Q9H2X6	HIPK2_HUMAN		Kd	5.77	CHEMBL
Homeodomain-interacting protein kinase 3	Kinase	Q9H422	HIPK3_HUMAN		Kd	6.41	CHEMBL
Homeodomain-interacting protein kinase 4	Kinase	Q8NE63	HIPK4_HUMAN		Kd	8.57	CHEMBL
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	6.16	CHEMBL
Serine/threonine-protein kinase TAO1	Kinase	Q7L7X3	TAOK1_HUMAN		Kd	6.27	CHEMBL
Serine/threonine-protein kinase TAO3	Kinase	Q9H2K8	TAOK3_HUMAN		Kd	5.57	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	7	CHEMBL
Homeodomain-interacting protein kinase 1	Kinase	Q86Z02	HIPK1_HUMAN		Kd	5.96	CHEMBL
Mitogen-activated protein kinase kinase kinase 1	Kinase	Q13233	M3K1_HUMAN		Kd	5.42	CHEMBL
Serine/threonine-protein kinase TAO2	Kinase	Q9UL54	TAOK2_HUMAN		Kd	6.27	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	6.72	CHEMBL
Myosin light chain kinase 3	Kinase	Q32MK0	MYLK3_HUMAN		Kd	5.02	CHEMBL
Serine/threonine-protein kinase A-Raf	Kinase	P10398	ARAF_HUMAN		IC50	8.15	CHEMBL
Receptor-interacting serine/threonine-protein kinase 3	Kinase	Q9Y572	RIPK3_HUMAN		IC50	4.84	CHEMBL
Mitogen-activated protein kinase 15	Kinase	Q8TD08	MK15_HUMAN		Kd	7.34	CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		Kd	5.14	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.93	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.71	CHEMBL
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.25	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.38	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.21	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	5.15	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.51	CHEMBL
Tyrosine-protein kinase ABL1	Kinase		ABL1_MOUSE		IC50	6.65	CHEMBL
Calcium-dependent protein kinase 1	Kinase		CDPK1_PLAF7		Kd	6.66	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase		VGFR2_MOUSE		IC50	7.82	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase		VGFR2_DANRE		IC50	5.59	CHEMBL
Purine nucleoside phosphorylase	Enzyme		Q8T9Z7_PLAFA		IC50	7.90	CHEMBL
Vascular endothelial growth factor receptor 3	Kinase		VGFR3_MOUSE	INHIBITOR	IC50	7.70	IUPHAR
Platelet-derived growth factor receptor beta	Kinase		PGFRB_MOUSE	INHIBITOR	IC50	7.24	IUPHAR
Serine/threonine-protein kinase B-raf	Kinase		BRAF_MOUSE		IC50	6.89	CHEMBL

External reference:

ID	Source
4025077	VUID
N0000175349	NUI
D06272	KEGG_DRUG
475207-59-1	SECONDARY_CAS_RN
4025077	VANDF
C1516119	UMLSCUI
CHEBI:50924	CHEBI
BAX	PDB_CHEM_ID
CHEMBL1336	ChEMBL_ID
CHEMBL1200485	ChEMBL_ID
D000077157	MESH_DESCRIPTOR_UI
DB00398	DRUGBANK_ID
5711	IUPHAR_LIGAND_ID
8234	INN_ID
9ZOQ3TZI87	UNII
216239	PUBCHEM_CID
495881	RXNORM
20792	MMSL
348700	MMSL
73580	MMSL
d05691	MMSL
011160	NDDF
011161	NDDF
420681006	SNOMEDCT_US
422042001	SNOMEDCT_US
432886002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sorafenib Tosylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1201	TABLET, FILM COATED	200 mg	ORAL	ANDA	29 sections
Sorafenib	HUMAN PRESCRIPTION DRUG LABEL	1	0480-5425	TABLET, FILM COATED	200 mg	ORAL	ANDA	27 sections
Sorafenib	HUMAN PRESCRIPTION DRUG LABEL	1	13668-682	TABLET, FILM COATED	200 mg	ORAL	ANDA	28 sections
sorafenib	HUMAN PRESCRIPTION DRUG LABEL	1	24979-715	TABLET, FILM COATED	200 mg	ORAL	ANDA	18 sections
sorafenib	HUMAN PRESCRIPTION DRUG LABEL	1	43598-458	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections
sorafenib	HUMAN PRESCRIPTION DRUG LABEL	1	43598-458	TABLET, FILM COATED	200 mg	ORAL	ANDA	26 sections
Nexavar	HUMAN PRESCRIPTION DRUG LABEL	1	50419-488	TABLET, FILM COATED	200 mg	ORAL	NDA	28 sections
Nexavar	HUMAN PRESCRIPTION DRUG LABEL	1	50419-488	TABLET, FILM COATED	200 mg	ORAL	NDA	28 sections
Sorafenib	HUMAN PRESCRIPTION DRUG LABEL	1	51407-760	TABLET, FILM COATED	200 mg	ORAL	ANDA	29 sections
Sorafenib	HUMAN PRESCRIPTION DRUG LABEL	1	51990-201	TABLET, FILM COATED	200 mg	ORAL	ANDA	29 sections